Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis

Fig. 3

Longitudinal levels of type VI collagen biomarkers in nintedanib, pirfenidone and untreated IPF patients. Serum levels of PRO-C6 (A) and C6M (B) are shown at baseline, six months and 12 months for pirfenidone (dark turquoise), nintedanib (turquoise) and non-treatment (grey) patients with IPF. Data are presented as geometric mean with 95% CI (error bars) adjusted for age and sex. The number of evaluable samples available for analysis at each time point is provided below the graphs. The interaction between timepoint and treatment was not significant forPRO-C6 (P = 0.87) and for C6M (P = 0.70). A significant average contrast across all timepoints between pirfenidone and non-treatment for C6M is shown as * (P < 0.05)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us